TD Waterhouse Canada Inc. raised its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 624.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 42,009 shares of the company’s stock after buying an additional 36,212 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Guardant Health were worth $7,352,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in GH. MCF Advisors LLC increased its stake in Guardant Health by 755.0% in the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after acquiring an additional 151 shares during the last quarter. NFSG Corp acquired a new position in Guardant Health during the third quarter valued at approximately $33,000. Ascentis Independent Advisors acquired a new position in Guardant Health during the first quarter valued at approximately $38,000. Hollencrest Capital Management bought a new stake in Guardant Health during the first quarter worth $41,000. Finally, TrinityBridge Ltd bought a new stake in Guardant Health during the second quarter worth $45,000. Institutional investors own 92.60% of the company’s stock.
Insider Activity
In related news, insider Chris Freeman sold 63,605 shares of Guardant Health stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the completion of the transaction, the insider owned 65,374 shares of the company’s stock, valued at $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 46,300 shares of Guardant Health stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This represents a 66.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 178,940 shares of company stock worth $30,070,911. 5.60% of the stock is owned by insiders.
Guardant Health Price Performance
Guardant Health stock opened at $157.88 on Tuesday. The stock’s 50 day moving average is $167.75 and its 200 day moving average is $139.99. The firm has a market cap of $21.19 billion, a P/E ratio of -45.24 and a beta of 1.58. Guardant Health, Inc. has a one year low of $65.96 and a one year high of $191.05.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.44) earnings per share. Equities analysts anticipate that Guardant Health, Inc. will post -3.02 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages have recently issued reports on GH. The Goldman Sachs Group reiterated a “buy” rating and issued a $210.00 price target on shares of Guardant Health in a research note on Friday, July 31st. Guggenheim boosted their price target on Guardant Health from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Royal Bank Of Canada upped their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Barclays raised their price objective on Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Stephens raised their price objective on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.00.
Check Out Our Latest Research Report on GH
Guardant Health Company Profile
Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.
The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.
Featured Stories
- Five stocks we like better than Guardant Health
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
